Report Detail

Pharma & Healthcare Degenerative Disc Disease - Pipeline Review, H2 2019

  • RnM3784255
  • |
  • 26 September, 2019
  • |
  • Global
  • |
  • 61 Pages
  • |
  • Global Markets Direct
  • |
  • Pharma & Healthcare

Degenerative Disc Disease - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Degenerative Disc Disease - Pipeline Review, H2 2019, provides an overview of the Degenerative Disc Disease (Musculoskeletal Disorders) pipeline landscape.

Degenerative disc disease is refers to degeneration of intervertebral discs of the spinal column. The main symptom of degenerative disc disease is pain, which often worsens during certain types of activity. Predisposing factors include aging and injury or trauma. Treatment includes non-steroidal anti-inflammatory drugs, muscle relaxants, pain relievers and antidepressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Degenerative Disc Disease - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 3, 2 and 1 respectively.

Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Degenerative Disc Disease (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Degenerative Disc Disease - Overview

              Degenerative Disc Disease - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Products under Development by Companies

                      Degenerative Disc Disease - Therapeutics Assessment

                        Assessment by Target

                          Assessment by Mechanism of Action

                            Assessment by Route of Administration

                              Assessment by Molecule Type

                                Degenerative Disc Disease - Companies Involved in Therapeutics Development

                                  AnGes Inc

                                    Bone Therapeutics SA

                                      CHA Bio & Diostech Co Ltd

                                        DiscGenics Inc

                                          Kolon TissueGene Inc

                                            U.S. Stem Cell Inc

                                              Yuhan Corp

                                                Degenerative Disc Disease - Drug Profiles

                                                  AdipoCell - Drug Profile

                                                    Product Description

                                                      Mechanism Of Action

                                                        R&D Progress

                                                          ALLOB - Drug Profile

                                                            Product Description

                                                              Mechanism Of Action

                                                                R&D Progress

                                                                  AMG-0101 - Drug Profile

                                                                    Product Description

                                                                      Mechanism Of Action

                                                                        R&D Progress

                                                                          AMG-0103 - Drug Profile

                                                                            Product Description

                                                                              Mechanism Of Action

                                                                                R&D Progress

                                                                                  CBAC-03 - Drug Profile

                                                                                    Product Description

                                                                                      Mechanism Of Action

                                                                                        R&D Progress

                                                                                          CybroCell - Drug Profile

                                                                                            Product Description

                                                                                              Mechanism Of Action

                                                                                                R&D Progress

                                                                                                  NTG-101 - Drug Profile

                                                                                                    Product Description

                                                                                                      Mechanism Of Action

                                                                                                        R&D Progress

                                                                                                          Stem Cell Therapy 1 for Degenerative Disc Disease - Drug Profile

                                                                                                            Product Description

                                                                                                              Mechanism Of Action

                                                                                                                R&D Progress

                                                                                                                  Stem Cell Therapy for Degenerative Disc Disease - Drug Profile

                                                                                                                    Product Description

                                                                                                                      Mechanism Of Action

                                                                                                                        R&D Progress

                                                                                                                          TG-D - Drug Profile

                                                                                                                            Product Description

                                                                                                                              Mechanism Of Action

                                                                                                                                R&D Progress

                                                                                                                                  X-0002 - Drug Profile

                                                                                                                                    Product Description

                                                                                                                                      Mechanism Of Action

                                                                                                                                        R&D Progress

                                                                                                                                          YH-14618 - Drug Profile

                                                                                                                                            Product Description

                                                                                                                                              Mechanism Of Action

                                                                                                                                                R&D Progress

                                                                                                                                                  Degenerative Disc Disease - Dormant Projects

                                                                                                                                                    Degenerative Disc Disease - Product Development Milestones

                                                                                                                                                      Featured News & Press Releases

                                                                                                                                                        Nov 14, 2018: Therapeutic potential of NTG-101, a single dose injectable treatment for Degenerative Disc Disease, demonstrated in preclinical large animal study published in Nature Publishing Group's "Scientific Reports"

                                                                                                                                                          Mar 20, 2018: USRM Chief Science Officer to Present at Paleo f(x) Ancestral Healing Conference in Austin, Texas

                                                                                                                                                            Feb 28, 2018: USRM Chief Science Officer to Present at Academy of Regenerative Practices Conference

                                                                                                                                                              Jan 15, 2018: USRM Reaches Key Sales Milestone of Proprietary Adipocell Product

                                                                                                                                                                Nov 28, 2017: Degenerative Disc Patients Significantly Improve With USRM’s Adipocell

                                                                                                                                                                  Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study

                                                                                                                                                                    Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial

                                                                                                                                                                      May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB® Phase IIA spinal fusion study

                                                                                                                                                                        Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the ‘Clinical Applications of Stem Cells’ Conference

                                                                                                                                                                          Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial

                                                                                                                                                                            Nov 17, 2014: Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease

                                                                                                                                                                              Sep 15, 2014: Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion

                                                                                                                                                                                Mar 26, 2014: Bioheart Announces Clinical Study for Degenerative Disc Disease

                                                                                                                                                                                  Appendix

                                                                                                                                                                                    Methodology

                                                                                                                                                                                      Coverage

                                                                                                                                                                                        Secondary Research

                                                                                                                                                                                          Primary Research

                                                                                                                                                                                            Expert Panel Validation

                                                                                                                                                                                              Contact Us

                                                                                                                                                                                                Disclaimer

                                                                                                                                                                                                Summary:
                                                                                                                                                                                                Get latest Market Research Reports on Degenerative Disc Disease. Industry analysis & Market Report on Degenerative Disc Disease is a syndicated market report, published as Degenerative Disc Disease - Pipeline Review, H2 2019. It is complete Research Study and Industry Analysis of Degenerative Disc Disease market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                                                                                                Last updated on

                                                                                                                                                                                                REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                                                                Purchase this Report

                                                                                                                                                                                                $2,000.00
                                                                                                                                                                                                $4,000.00
                                                                                                                                                                                                $6,000.00
                                                                                                                                                                                                1,600.00
                                                                                                                                                                                                3,200.00
                                                                                                                                                                                                4,800.00
                                                                                                                                                                                                1,868.00
                                                                                                                                                                                                3,736.00
                                                                                                                                                                                                5,604.00
                                                                                                                                                                                                315,880.00
                                                                                                                                                                                                631,760.00
                                                                                                                                                                                                947,640.00
                                                                                                                                                                                                166,860.00
                                                                                                                                                                                                333,720.00
                                                                                                                                                                                                500,580.00
                                                                                                                                                                                                Credit card Logo

                                                                                                                                                                                                Related Reports


                                                                                                                                                                                                Reason to Buy

                                                                                                                                                                                                Request for Sample of this report